WAG
REGN icon

Winthrop Advisory Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Winthrop Advisory Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-273
Closed -$211K – 232
2026
Q1 		$211K Buy
+273
New +$209K 0.02% 181
2024
Q4 		– Sell
-285
Closed -$300K – 168
2024
Q3 		$300K Sell
285
-2
-0.7% -$2.23K 0.04% 115
2024
Q2 		$302K Sell
287
-8
-3% -$7.75K 0.04% 109
2024
Q1 		$284K Sell
295
-5
-2% -$4.75K 0.04% 119
2023
Q4 		$263K Buy
+300
New +$247K 0.04% 115

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Winthrop Advisory Group's REGN Position: Q2 2026 in Review

Winthrop Advisory Group sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 273 shares — an estimated $211K sold.

Winthrop Advisory Group first reported a position in REGN in Q4 2023 and held it in 5 quarters. The position peaked at $302K in Q2 2024. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Winthrop Advisory Group reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Winthrop Advisory Group sold 273 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $211K.
  • Winthrop Advisory Group first reported a position in Regeneron Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Winthrop Advisory Group's Regeneron Pharmaceuticals position peaked at $302K in Q2 2024.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Winthrop Advisory Group's 13F filing for Q2 2026, filed 17 Jul 2026.